Karen L. Smith Insider Trading Transactions

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for Karen L. Smith.

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of Karen L. Smith. Karen L. Smith is Director in ANTARES PHARMA, INC. ($ATRS) and Director in SANGAMO THERAPEUTICS, INC ($SGMO) and EVP, R&D and CMO in Jazz Pharmaceuticals plc ($JAZZ) and Global Head of R&D and CMO in Jazz Pharmaceuticals plc ($JAZZ) and Director in ACCELERON PHARMA INC ($XLRN) and Director in Sucampo Pharmaceuticals, Inc. ($SCMP) and EVP, Chief Medical Officer in Emergent BioSolutions Inc. ($EBS).

Latest Insider Trading Transactions of Karen L. Smith

	1 Week	2 Weeks	1 Month	3 Months	6 Months	1 Year	2 Years
No. of Purchases	0	0	0	0	0	0	0
Value of Purchases ($)	0	0	0	0	0	0	0
No. of Sales	0	0	0	0	0	0	0
Value of Sales ($)	0	0	0	0	0	0	0

Sentiment: All, XLRN, ATRS, EBS, JAZZ, SGMO, SCMP

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	M	52.99	2,050	108,630	4,085
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	M	41.64	1,875	78,075	3,750
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	M	35.34	5,000	176,700	10,000
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Sell	S	141.15	641	90,477	1,622	2.3 K to 1.6 K (-28.33 %)
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Sell	S	140.13	11,223	1,572,679	2,263	13.5 K to 2.3 K (-83.22 %)
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Buy	M	52.99	2,050	108,630	13,486	11.4 K to 13.5 K (+17.93 %)
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Buy	M	41.64	1,875	78,075	11,436	9.6 K to 11.4 K (+19.61 %)
Apr 05 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Buy	M	35.34	5,000	176,700	9,561	4.6 K to 9.6 K (+109.63 %)
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	M	52.99	2,050	108,630	6,135
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	M	41.64	1,875	78,075	5,625
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	M	35.34	5,000	176,700	15,000
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Sell	S	137.92	941	129,783	4,561	5.5 K to 4.6 K (-17.10 %)
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Sell	S	136.92	3,796	519,748	5,502	9.3 K to 5.5 K (-40.83 %)
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Sell	S	136.22	2,987	406,889	9,298	12.3 K to 9.3 K (-24.31 %)
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Sell	S	134.54	1,201	161,583	12,285	13.5 K to 12.3 K (-8.91 %)
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Buy	M	52.99	2,050	108,630	13,486	11.4 K to 13.5 K (+17.93 %)
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Buy	M	41.64	1,875	78,075	11,436	9.6 K to 11.4 K (+19.61 %)
Apr 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Buy	M	35.34	5,000	176,700	9,561	4.6 K to 9.6 K (+109.63 %)
Mar 01 2021	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Option Exercise	A	11.19	16,400	183,516	16,400
Mar 01 2021	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Grant	A	0.00	8,200	0	25,700	17.5 K to 25.7 K (+46.86 %)
Feb 26 2021	EBS	Emergent BioSoluti ...	Smith Karen L.	EVP, Chief Medical ...	Option Exercise	A	93.49	11,765	1,099,910	11,765
Feb 26 2021	EBS	Emergent BioSoluti ...	Smith Karen L.	EVP, Chief Medical ...	Grant	A	0.00	2,941	0	12,193	9.3 K to 12.2 K (+31.79 %)
Feb 26 2021	EBS	Emergent BioSoluti ...	Smith Karen L.	EVP, Chief Medical ...	Grant	A	0.00	2,942	0	9,252	6.3 K to 9.3 K (+46.62 %)
Feb 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	A	115.53	3,222	372,238	3,222
Feb 02 2021	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Grant	A	0.00	1,622	0	4,561	2.9 K to 4.6 K (+55.19 %)
Jun 15 2020	ATRS	ANTARES PHARMA, IN ...	Smith Karen L.	Director	Option Exercise	A	2.73	58,246	159,012	58,246
Jun 15 2020	ATRS	ANTARES PHARMA, IN ...	Smith Karen L.	Director	Grant	A	2.73	30,220	82,501	54,193	24 K to 54.2 K (+126.06 %)
Jun 15 2020	ATRS	ANTARES PHARMA, IN ...	Smith Karen L.	Director	Option Exercise	A	2.73	58,246	159,012	58,246
Jun 15 2020	ATRS	ANTARES PHARMA, IN ...	Smith Karen L.	Director	Grant	A	2.73	30,220	82,501	54,193	24 K to 54.2 K (+126.06 %)
May 20 2020	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Option Exercise	A	10.46	15,000	156,900	15,000
May 20 2020	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Grant	A	0.00	2,500	0	10,000	7.5 K to 10 K (+33.33 %)
Jan 24 2020	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	A	52.99	8,185	433,723	8,185
Jan 24 2020	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Grant	A	0.00	1,377	0	2,939	1.6 K to 2.9 K (+88.16 %)
Jun 14 2019	ATRS	ANTARES PHARMA, IN ...	Smith Karen L.	Director	Option Exercise	A	2.92	46,729	136,449	46,729
Jun 14 2019	ATRS	ANTARES PHARMA, IN ...	Smith Karen L.	Director	Grant	A	2.92	23,973	70,001	23,973	0 to 24 K
Jun 12 2019	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Option Exercise	A	9.38	15,000	140,700	15,000
Jun 12 2019	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Grant	A	0.00	2,500	0	7,500	5 K to 7.5 K (+50.00 %)
Jan 29 2019	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	A	41.64	7,500	312,300	7,500
Jan 29 2019	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Grant	A	0.00	1,250	0	1,562	312 to 1.6 K (+400.64 %)
Jun 28 2018	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Option Exercise	A	15.65	30,000	469,500	30,000
Jun 28 2018	SGMO	SANGAMO THERAPEUTI ...	Smith Karen L.	Director	Grant	A	0.00	5,000	0	5,000	0 to 5 K
Mar 07 2018	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	EVP, R&D and CMO	Payment of Exercise	F	143.39	648	92,917	28,474	29.1 K to 28.5 K (-2.23 %)
Mar 05 2018	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	A	40.61	1,875	76,144	1,875
Mar 05 2018	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Grant	A	0.00	312	0	312	0 to 312
Mar 05 2018	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	EVP, R&D and CMO	Option Exercise	A	140.67	19,290	2,713,524	19,290
Mar 05 2018	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	EVP, R&D and CMO	Option Exercise	A	140.67	710	99,876	710
Mar 05 2018	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	EVP, R&D and CMO	Grant	A	0.00	8,000	0	29,122	21.1 K to 29.1 K (+37.88 %)
Feb 13 2018	SCMP	Sucampo Pharmaceut ...	Smith Karen L.	Director	Option Exercise	D	10.95	30,000	328,500	0
Nov 15 2017	XLRN	ACCELERON PHARMA I ...	Smith Karen L.	Director	Option Exercise	A	35.34	20,000	706,800	20,000
May 12 2017	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	EVP, R&D and CMO	Option Exercise	A	155.18	2,500	387,950	2,500
May 12 2017	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	EVP, R&D and CMO	Grant	A	0.00	1,000	0	21,527	20.5 K to 21.5 K (+4.87 %)
May 12 2017	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	EVP, R&D and CMO	Payment of Exercise	F	155.18	641	99,470	20,527	21.2 K to 20.5 K (-3.03 %)
Mar 06 2017	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Option Exercise	A	136.18	17,848	2,430,541	17,848
Mar 06 2017	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Option Exercise	A	136.18	902	122,834	902
Mar 06 2017	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Grant	A	0.00	7,500	0	21,168	13.7 K to 21.2 K (+54.87 %)
Aug 12 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Buy	P	137.26	1	137	14,182	14.2 K to 14.2 K (+0.01 %)
Aug 12 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Buy	P	137.10	607	83,218	14,181	13.6 K to 14.2 K (+4.47 %)
Jul 13 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Buy	P	143.63	580	83,305	13,574	13 K to 13.6 K (+4.46 %)
Jun 15 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Buy	P	149.61	557	83,335	12,994	12.4 K to 13 K (+4.48 %)
May 12 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Payment of Exercise	F	148.76	641	95,355	12,399	13 K to 12.4 K (-4.92 %)
Feb 29 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Option Exercise	A	123.36	14,375	1,773,300	14,375
Feb 29 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Option Exercise	A	123.36	625	77,100	625
Feb 29 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Grant	A	0.00	6,000	0	13,143	7.1 K to 13.1 K (+84.00 %)
Apr 15 2016	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Payment of Exercise	F	147.34	103	15,176	13,040	13.1 K to 13 K (-0.78 %)
May 13 2015	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Option Exercise	A	176.51	15,516	2,738,729	15,516
May 13 2015	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Option Exercise	A	176.51	2,264	399,619	2,264
May 13 2015	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Grant	A	0.00	275	0	7,105	6.8 K to 7.1 K (+4.03 %)
May 13 2015	JAZZ	Jazz Pharmaceutica ...	Smith Karen L.	Global Head of R&D ...	Grant	A	0.00	6,830	0	6,830	0 to 6.8 K

Page: 1